Quarter
Charts🇺🇸US Markets

ETON PHARMACEUTICALS, INC.

ETON

CIK 0001710340 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$21M
↑+82.7% +$10Mvs FY2024 (Q4)
Operating Income
$519K
↓-91.5% -$6Mvs FY2024 (Q4)
Gross Profit
$13M
↑+102.3% +$7Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
60/100
  • Profitability
    0ROIC -1.4% (10% = solid, 20%+ = moat)
  • Liquidity
    54Current Ratio 1.57 (above 1.5 = solid)
  • Leverage
    58D/E 0.83 (under 0.5 = conservative)
  • Efficiency
    47Asset Turnover 0.81x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +82.7% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 2.4% · trend +9.0pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project ETON's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

25%

Trailing 3-yr CAGR was 28.7%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$12.63
Total enterprise IV
$340M
Diluted shares
0.03B
Terminal PV
$264M (78% of total)
Year-5 FCF
$31M
YearProjected FCFDiscounted PV
+1$13M$12M
+2$16M$13M
+3$20M$15M
+4$25M$17M
+5$31M$19M
Terminal$425M$264M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$333K
investment in PP&E
Stock-based comp (TTM)
$6M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$92M
everything owned
Total liabilities
$66M
everything owed
Stockholders' equity
$26M
shareholder claim
Net debt
$-4M
Net cash position ($4M)

Recent performance · 34 quarters

Revenue↑+82.7% +$10M
$21M
Net Income↓-407.3% -$3M
$-2M
Free Cash Flow↓-308.3% -$37K
$-49K
Operating Margin
2.4%

Drill down

ETON Sankey

See ETON PHARMACEUTICALS, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

ETON Charts

34 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

ETON Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics